The BCR Knockout Jurkat Polyclonal Cells are a pool of CRISPR/Cas9-edited Jurkat T lymphocytes carrying targeted disruption of the BCR (Breakpoint Cluster Region) gene. This polyclonal knockout population provides a genetically heterogeneous model system for studying BCR functional loss in a human T-cell context, without selection for a single clonal editing outcome.
Jurkat cells are an immortalized human T lymphocyte line originally derived from the peripheral blood of a patient with acute T-cell leukemia. These suspension cells are widely employed as a model for T-cell receptor signaling, apoptosis, and leukemogenesis. The Jurkat background enables investigation of BCR-related mechanisms in the context of T-cell biology and lymphoid malignancy.
BCR encodes a multifunctional protein possessing intrinsic serine/threonine kinase activity and acting as a GTPase-activating protein (GAP) for the Rho-family small GTPases RAC1 and CDC42. Through its GAP domain, BCR promotes GTP hydrolysis on RAC1 and CDC42, thereby downregulating their active states and influencing cytoskeletal reorganization, cell polarity, and migration. In addition, BCR serves as a scaffold assembling signaling complexes; it interacts with ABL1 kinase, GRB2, CRK, and PIK3R1, integrating signals from tyrosine kinase receptors and integrins. Within the RAC1/CDC42 signaling axis, BCR functions upstream of PAK, LIMK, and cofilin, thereby regulating actin dynamics. Furthermore, BCR modulates MAPK pathways, including JNK and p38 MAPK, which are downstream of RAC1/CDC42 and contribute to transcriptional responses affecting proliferation and survival.
In Jurkat T cells, disruption of BCR allows dissection of its role in T-cell receptor-proximal signaling and cytoskeletal remodeling. Given that Jurkat cells exhibit high proliferative capacity and leukemic origin, BCR loss-of-function can be evaluated in the context of abnormal signal transduction pathways relevant to leukemia. Because BCR interacts with ABL1, which is commonly dysregulated in hematopoietic malignancies, this knockout model may be particularly informative for studying BCR-ABL-dependent signaling cascades and resistance mechanisms to ABL kinase inhibitors like imatinib.
Researchers can employ these polyclonal BCR knockout Jurkat cells in a variety of experimental settings, including Western blot analysis to verify BCR ablation and assess phosphorylation levels of RAC1, CDC42, PAK, LIMK, and cofilin. Co-immunoprecipitation experiments can confirm loss of BCR interaction with partners such as ABL1, GRB2, and CRK. Functional studies using flow cytometry can evaluate actin polymerization dynamics, while migration and invasion assays measure the impact on cell motility. RT-qPCR can profile transcriptional changes in downstream effectors including JNK and p38 MAPK. In oncology research, drug sensitivity assays with imatinib or other tyrosine kinase inhibitors can reveal BCR-dependent drug responses, and transcriptomic profiling via RNA-seq permits global evaluation of signaling network alterations. For further information or custom requirements, please contact Ascent Research.
